Drug Profile
Iadademstat - Oryzon Genomics
Alternative Names: ORY 1001; RG 6016; RO-7051790Latest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator Ministry of Economy and Competitiveness; Oryzon
- Developer Fox Chase Cancer Center; Oryzon; Roche
- Class Antineoplastics; Cyclohexanes; Cyclopropanes; Diamines; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Neuroendocrine tumours; Small cell lung cancer
- Preclinical Sickle cell anaemia
- No development reported Acute biphenotypic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 06 Mar 2024 Oryzon Genomics in collaboration with National Cancer Institute (NCI) plans a phase I/II trial in Small cell lung cancer (Combination therapy) in May 2024 (PO) (NCT06287775)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Second-line therapy or greater) in Canada (PO)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Second-line therapy or greater) in Denmark (PO)